Navigation Links
Genomic Health Announces Appointment of Ginger Graham to Board of Directors
Date:12/8/2008

REDWOOD CITY, Calif., Dec. 8 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the appointment of Ginger L. Graham to its board of directors. Ms. Graham is the former President and CEO of Amylin Pharmaceuticals, Inc.; a biopharmaceutical company dedicated to developing innovative medicines to improve the lives of people with diabetes and obesity. Prior to Amylin, Ms. Graham served as Group Chairman, Office of the President, for Guidant Corporation, a cardiovascular medical device manufacturer, and held a number of management positions at Eli Lilly and Company, a global pharmaceutical company.

"Ginger brings a wealth of industry leadership experience to Genomic Health's board of directors, with expertise in developing and commercializing successful products for pharmaceutical and medical device companies," said Randy Scott, Ph.D., chairman and CEO of Genomic Health. "Her appointment comes at an opportune time as we continue to expand our commercial efforts outside of the United States and invest in our product pipeline, as part of our mission to make individualized treatment standard practice for all cancer patients."

Ms. Graham received a Bachelor of Science in agricultural economics from the University of Arkansas. She also holds a Master of Business Administration from Harvard University.

About Oncotype DX(R)

Oncotype DX is the first and only multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. Additionally, the test report provides quantitative scores for certain individual genes. Oncotype DX has been extensively evaluated in eleven clinical studies involving more than 4,000 breast cancer pati
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference
2. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
3. Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS
4. Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products Neurodegenerative Diagnostics
5. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
6. Transgenomic Awarded SBIR Grant to Support Development of SURVEYOR(R) Endonuclease Adaptor-ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation
7. Genomic Health to Present at Stephens Fall Investment Conference
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. NeoGenomics to Present at the Rodman & Renshaw Healthcare Conference on November 10
10. Transgenomic to Present at Rodman & Renshaw 10th Annual Healthcare Conference
11. /C O R R E C T I O N -- Rosetta Genomics Ltd/
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Continental Clinical Solutions, LLC (Continental) focuses ... at its mid-Atlantic late-phase research facility, located in ... the idea of closing patient disparities in mind. ... advances," said Continental's CEO, Saleh Stevens . ... cell line of Henrietta Lacks, dubious ethical practices ...
(Date:11/23/2014)... November 23, 2014 Apiscent Labs, ... of fine chemical ingredients to the global pharmaceutical ... of its new website, Apiscent.com. , The Apiscent.com ... Labs, clean design, easy navigation, rotating images and ... Labs stand out. , The company’s ...
(Date:11/22/2014)... 2014 RURO, Inc., a leading ... released Limfinity® version 5.1.4. , RURO’s deployment teams ... than ever in RURO’s 8 year history. Many ... enhancement. Limfinity® version 5.1.4 is the perfect example ... bug fixes! , Limfinity® 5.1.4 release highlights – ...
(Date:11/22/2014)...   , ... zu KLOX    Mariano ... Officer bestellt    KLOX ist bestens ... zugelassenen Behandlungssystems zur Wundheilung zu beginnen    , ... sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
Breaking Biology Technology:At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3RURO Announces Limfinity® version 5.1.4 2KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5
... against osteoporosis-related fractures, including spine and hip, - Reclast reduced ... to placebo in study published in New England Journal of Medicine, - Unique ... ... - Osteoporotic fractures affect one in two women over 50(1) and are ...
... a biotechnology company developing pharmaceutical products for use ... financing deal. The majority of the funding, $2.3 ... remainder was borrowed from the Madison Development Corporation, ... a private investment firm. The funds raised will ...
... the next strange idea you hear strange: the person ... door. , ,A panel of experienced entrepreneurs speaking ... Milwaukee last Wednesday have dealt with looks and whispers ... in the audience to accept the whispers as a ...
Cached Biology Technology:Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 2Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 3Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 4Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 5Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 6Quintessence Secures Financing 2Quintessence Secures Financing 3Lowering the fear factor for entrepreneurs, intra-preneurs 2Lowering the fear factor for entrepreneurs, intra-preneurs 3
(Date:11/4/2014)... Nov. 5, 2014 – University of Utah engineers developed ... help jet fuel produce electricity without needing to ignite ... to power portable electronics, off-grid power and sensors. , ... in the American Chemical Society journal ACS Catalysis ... a chemical reaction between a fuel and an oxygen-rich ...
(Date:11/4/2014)...   3D scanner ... Fuel3D , a developer of 3D scanning solutions, ... $6.4 million (£4 million). This funding builds on the company,s ... and paves the way for the commercial launch of the ... round was led by Chimera Partners and will be used ...
(Date:11/3/2014)... 3, 2014  NeuroSigma ® , Inc. (NeuroSigma), ... company focused on commercialization of its non-invasive ... treatment of neurological and neuropsychiatric disorders, announced today ... issued a Notice of Allowance for Mexican Patent ... by NeuroSigma and the Regents of the University ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... Education Association (SEA) is preparing to conduct the first-ever research ... debris in the North Atlantic Ocean. The ... 20-year data set previously collected by SEA that reveals a ... in the western North Atlantic Ocean. This trip ...
... from the University of Warwick has discovered taking too much ... your cholesterol by almost 10%. Selenium is a trace ... from foods such as vegetables, meat and seafood. However, when ... selenium, such as through taking selenium supplements, it can have ...
... , This release is available in French ... more than 3 times per week show a worse performance in ... of exposure to mercury show a generalised delay in cognitive, memory ... fish and canned fish and to a lesser extent in white ...
Cached Biology News:SEA to conduct expedition dedicated to measuring plastic marine debris in the North Atlantic Ocean 2Too much selenium can increase your cholesterol 2Consumption of certain fish during pregnancy associated with poorer cognitive performance 2
... cells (BTI-TN-5B1-4) derived from Trichoplusia ni ... to be capable of expressing significantly ... compared to other insect cells. High ... doubling time as adherent cultures- Quick adaptation ...
... assay system offers the following ... for batch-processing systems, Long lasting ... microplates such as 384-well and ... storage conditions ( 2 - ...
... universal lysis buffer, PCR mix, DNA polymerase ... l volume PCR reactions. This system can ... positive rod and coccus bacteria, such as ... Aureus, Streptococcus Agalactiae, and etc. With the ...
... Staining Kit is uniquely formulated to ... minimal protein modification for optimal mass ... associated with traditional silver stains are ... the reagents used do not modify ...
Biology Products: